Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

This study has been terminated.

(Business Decision; No Safety or Efficacy Concerns (see below).)

Sponsor:

Information provided by (Responsible Party):

Takeda

ClinicalTrials.gov Identifier:

NCT01677182

First received: August 29, 2012

Last updated: January 8, 2015

Last verified: January 2015

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	September 2014
Primary Completion Date:	September 2014 (Final data collection date for primary outcome measure)